PARP inhibitors: a new horizon for patients with prostate cancer
B Congregado, I Rivero, I Osmán, C Sáez… - Biomedicines, 2022 - mdpi.com
The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …
PARP inhibitors in prostate cancer
P Ramakrishnan Geethakumari, MJ Schiewer… - … treatment options in …, 2017 - Springer
Opinion Statement The genomic landscape of metastatic prostate cancer (mPCa) reveals
that up to 90% of patients harbor actionable mutations and> 20% have somatic DNA repair …
that up to 90% of patients harbor actionable mutations and> 20% have somatic DNA repair …
PARP inhibition, a new therapeutic avenue in patients with prostate cancer
Up to 25% of patients with metastatic prostate cancer present with germline or somatic DNA
damage repair alterations, some of which are associated with aggressive disease and poor …
damage repair alterations, some of which are associated with aggressive disease and poor …
Advances in PARP inhibitors for prostate cancer
S Tisseverasinghe, B Bahoric, M Anidjar, S Probst… - Cancers, 2023 - mdpi.com
Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …
PARP inhibitors in prostate cancer–the preclinical rationale and current clinical development
Prostate cancer is globally the second most commonly diagnosed cancer type in men.
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …
PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what's now, what's new, and what's coming?
A Marchetti, M Rosellini, G Nuvola, E Tassinari… - Cancers, 2022 - mdpi.com
Simple Summary Prostate cancer still represents an important health problem in men,
considering its high frequency. Over the last decade, novel treatment options have emerged …
considering its high frequency. Over the last decade, novel treatment options have emerged …
PARP inhibitors in metastatic prostate cancer: evidence to date
E Nizialek, ES Antonarakis - Cancer management and research, 2020 - Taylor & Francis
Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents
that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either …
that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either …
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
GM Iannantuono, E Chandran, CS Floudas… - Cancer Treatment …, 2023 - Elsevier
Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …
[HTML][HTML] The biology behind combining PARP and androgen receptor inhibition for metastatic castration resistant prostate cancer
For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
[HTML][HTML] When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials
ES Antonarakis, LG Gomella, DP Petrylak - European urology oncology, 2020 - Elsevier
Context The goal of precision oncology is to use the underlying genomic characteristics of
the patient and the cancer to select the optimal treatment at a given time. The recent Food …
the patient and the cancer to select the optimal treatment at a given time. The recent Food …